Prologis Pharmaceutical announced that Zhejiang Projiayuan Pharmaceutical Co., Ltd., a wholly-owned subsidiary, has received the “Notice of Approval Notice for the Marketing Application of Chemical Ingredients” for the raw drug deuterium enzalutamide issued by the State Drug Administration. The specification is 15kg/barrel, notification number 2026YS00917. The approval conclusion is that it complies with the relevant requirements for drug registration and approves registration.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.